13F Pro

SEC Form 4 reporting owner

Orbimed Advisors LLC

Orbimed Advisors LLC has filed 57 Form 4 transactions reported between November 21, 2025 and September 21, 2026, as Director of Electra Therapeutics, Inc., Director of BlossomHill Therapeutics, Inc., Director of Braveheart Bio, Inc., Director of Scribe Therapeutics, Inc., Director of Sionna Therapeutics, Inc., 10% owner of Enliven Therapeutics, Inc., Director of Shattuck Labs, Inc., Director of Q32 Bio Inc., Director of Prelude Therapeutics Inc, 10% owner of Traws Pharma, Inc., Director of ImageneBio, Inc., 10% owner of Adicet Bio, Inc. and Director of Keros Therapeutics, Inc..

Name as filed: ORBIMED ADVISORS LLC

Open-market buys, 24 mo
$73.5M
9 lines
Open-market sales, 24 mo
$103.2M
27 lines
Companies
13
with Form 4 filings
Latest transaction
Sep 21, 2026
transaction date

Roles and reported holdings

  • ETRAElectra Therapeutics, Inc.
    Sep 21, 2026

    Director

    Held indirectly (latest line)1,758,279 sh as of Sep 21, 2026 · Form 4

    24 months: $20.0M bought

  • BLSMBlossomHill Therapeutics, Inc.
    Aug 10, 2026

    Director

    Held indirectly (latest line)2,714,279 sh as of Aug 10, 2026 · Form 4

    24 months: $10.0M bought

  • BRVEBraveheart Bio, Inc.
    Aug 7, 2026

    Director

    No common-stock holding reported on a purchase, sale, gift or withholding line.

    2 lines are priced far from BRVE’s market price that day, so the filing may concern a different security. Left out of totals and holdings; see the filings.

  • SCTXScribe Therapeutics, Inc.
    Jul 27, 2026

    Director

    Held indirectly (latest line)1,348,825 sh as of Jul 27, 2026 · Form 4

    24 months: $15.0M bought

  • SIONSionna Therapeutics, Inc.
    Dec 17, 2025 – Jul 7, 2026

    Director

    Held indirectly (latest line)2,469,959 sh as of Jul 7, 2026 · Form 4

    24 months: $50.9M sold

  • ELVNEnliven Therapeutics, Inc.
    Jun 15, 2026 – Jun 22, 2026

    10% owner

    Held indirectly (latest line)6,555,102 sh as of Jun 22, 2026 · Form 4

    24 months: $51.7M sold

  • STTKShattuck Labs, Inc.
    Jun 8, 2026 – Jun 11, 2026

    Director

    Held indirectly (latest line)5,303,908 sh as of Jun 11, 2026 · Form 4
  • QTTBQ32 Bio Inc.
    May 28, 2026

    Director

    Held indirectly (latest line)625,000 sh as of May 28, 2026 · Form 4

    24 months: $15.0M bought

  • PRLDPrelude Therapeutics Inc
    Apr 21, 2026

    Director

    Held indirectly (latest line)1,126,126 sh as of Apr 21, 2026 · Form 4

    24 months: $12.5M bought

  • TRAWTraws Pharma, Inc.
    Apr 16, 2026

    10% owner

    Held indirectly (latest line)1,793,187 sh as of Apr 16, 2026 · Form 4

    24 months: $998K bought

  • IMAImageneBio, Inc.
    Apr 14, 2026

    Director

    Held indirectly (latest line)384,689 sh as of Apr 14, 2026 · Form 4
  • ACETAdicet Bio, Inc.
    Apr 7, 2026 – Apr 8, 2026

    10% owner

    Held indirectly (latest line)0 sh as of Apr 8, 2026 · Form 4

    24 months: $675K sold

  • KROSKeros Therapeutics, Inc.
    Nov 21, 2025

    Director

    No common-stock holding reported on a purchase, sale, gift or withholding line.

Transaction history

All 57 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Sep 21, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by GORDON CARL L1,000,000$15.0M@ $15.00Form 4
Sep 21, 2026ETRADirectorConversion of derivativeCode C · indirect758,279—Form 4
Sep 21, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by GORDON CARL L333,333$5.0M@ $15.00Form 4
Sep 21, 2026ETRADirectorConversion of derivativeCode C · indirect1,703,314—Form 4
Sep 21, 2026ETRADirectorConversion of derivativeCode C · indirect1,087,934—Form 4
Sep 21, 2026ETRADirectorConversion of derivativeCode C · indirect2,002,310—Form 4
Aug 10, 2026BLSMDirectorOpen-market purchaseCode P · indirectAlso reported by GORDON CARL L625,000$10.0M@ $16.00Form 4
Aug 10, 2026BLSMDirectorConversion of derivativeCode C · indirect1,049,283—Form 4
Aug 10, 2026BLSMDirectorConversion of derivativeCode C · indirect1,039,996—Form 4
Aug 7, 2026BRVEDirectorConversion of derivativeCode C · indirect40,000,000—Form 4
Aug 7, 2026BRVEDirectorOpen-market purchaseCode P · indirectPrice far from market; may be another securityAlso reported by Chimovits Erez273,333$4.9M@ $18.00Form 4
Aug 7, 2026BRVEDirectorOpen-market purchaseCode P · indirectPrice far from market; may be another securityAlso reported by Chimovits Erez1,666,667$30.0M@ $18.00Form 4
Aug 7, 2026BRVEDirectorConversion of derivativeCode C · indirect9,132,420—Form 4
Jul 27, 2026SCTXDirectorConversion of derivativeCode C · indirect2,065,672—Form 4
Jul 27, 2026SCTXDirectorOpen-market purchaseCode P · indirectAlso reported by GORDON CARL L1,000,000$15.0M@ $15.00Form 4
Jul 27, 2026SCTXDirectorConversion of derivativeCode C · indirect348,825—Form 4
Jul 7, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by Thompson Peter A.85,918$3.9M@ $44.86Form 4
Jun 30, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by Thompson Peter A.115,844$5.3M@ $45.50Form 4
Jun 22, 2026ELVN10% ownerOpen-market saleCode S · indirect46,776$2.1M@ $45.00Form 4
Jun 22, 2026ELVN10% ownerOpen-market saleCode S · indirect787,024$35.7M@ $45.38Form 4
Jun 22, 2026ELVN10% ownerOpen-market saleCode S · indirect1,477$66K@ $45.00Form 4
Jun 22, 2026ELVN10% ownerOpen-market saleCode S · indirect24,846$1.1M@ $45.38Form 4
Jun 15, 2026ELVN10% ownerOpen-market saleCode S · indirect272,322$12.3M@ $45.02Form 4
Jun 15, 2026ELVN10% ownerOpen-market saleCode S · indirect9,086$409K@ $45.02Form 4
Jun 11, 2026STTKDirectorOpen-market purchaseCode P · indirect208,333—Form 4
Jun 11, 2026STTKDirectorOpen-market purchaseCode P · indirect1,041,667—Form 4
Jun 8, 2026STTKDirectorConversion of derivativeCode C · indirect3,073,298—Form 4
Jun 8, 2026STTKDirectorConversion of derivativeCode C · indirect15,366,490—Form 4
May 28, 2026QTTBDirectorOpen-market purchaseCode P · indirectAlso reported by Xu Diyong625,000$5.0M@ $8.00Form 4
May 28, 2026QTTBDirectorOpen-market purchaseCode P · indirectAlso reported by Xu Diyong1,250,000$10.0M@ $8.00Form 4
May 27, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by Thompson Peter A.101$4K@ $44.49Form 4
May 11, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by Thompson Peter A.184,639$8.5M@ $46.22Form 4
May 8, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by Thompson Peter A.59,767$2.7M@ $44.58Form 4
May 7, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by Thompson Peter A.48,546$2.2M@ $44.61Form 4
Apr 21, 2026PRLDDirectorOpen-market purchaseCode P · indirectAlso reported by Bonita David P1,126,126$5.0M@ $4.44Form 4
Apr 21, 2026PRLDDirectorOpen-market purchaseCode P · indirectAlso reported by Bonita David P1,689,189$7.5M@ $4.44Form 4
Apr 18, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by Thompson Peter A.2,948$131K@ $44.52Form 4
Apr 17, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by Thompson Peter A.52,397$2.3M@ $44.68Form 4
Apr 16, 2026TRAW10% ownerOpen-market purchaseCode P · indirect1,793,187—Form 4
Apr 16, 2026TRAW10% ownerOpen-market purchaseCode P · indirect597,729$998K@ $1.67Form 4
Apr 16, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by Thompson Peter A.226,906$10.3M@ $45.34Form 4
Apr 15, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by Thompson Peter A.235,863$10.5M@ $44.64Form 4
Apr 14, 2026IMADirectorOpen-market purchaseCode P · indirect384,689—Form 4
Apr 14, 2026IMADirectorOpen-market purchaseCode P · indirect336,603—Form 4
Apr 14, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by Thompson Peter A.47,814$2.1M@ $44.51Form 4
Apr 8, 2026ACET10% ownerOpen-market saleCode S · indirect40,416$264K@ $6.52Form 4
Apr 8, 2026ACET10% ownerOpen-market saleCode S · indirect32,523$205K@ $6.29Form 4
Apr 7, 2026ACET10% ownerOpen-market saleCode S · indirect2,400$15K@ $6.38Form 4
Apr 7, 2026ACET10% ownerOpen-market saleCode S · indirect29,319$191K@ $6.53Form 4
Feb 3, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by Thompson Peter A.29,063$1.3M@ $44.58Form 4
Feb 2, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by Thompson Peter A.1,890$84K@ $44.57Form 4
Dec 24, 2025SIONDirectorOpen-market saleCode S · indirectAlso reported by Thompson Peter A.33,356$1.5M@ $44.55Form 4
Dec 19, 2025SIONDirectorOpen-market saleCode S · indirectAlso reported by Thompson Peter A.875$39K@ $44.49Form 4
Dec 18, 2025SIONDirectorOpen-market saleCode S · indirectAlso reported by Thompson Peter A.100$4K@ $44.49Form 4
Dec 17, 2025SIONDirectorOpen-market saleCode S · indirectAlso reported by Thompson Peter A.900$40K@ $44.50Form 4
Nov 21, 2025KROSDirectorDisposition to issuerCode D · indirect74,465$1.3M@ $17.75Form 4
Nov 21, 2025KROSDirectorDisposition to issuerCode D · indirect140,057$2.5M@ $17.75Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

2 open-market lines are priced outside 0.67×–1.5× of the stock’s closing price that day. A gap that large usually means the filing reports a different security than the company it is filed under, so those lines are shown but left out of totals and holdings.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.